Abstract
The discovery of the inhibitors of 3-hydroxy-3-methylglutaryl- coenzyme A (HMG-CoA) reductase (so called statins) is a great step forward in clinical pharmacology and therapeutics. Substantial clinical evidence suggests that statins are effective in the primary and secondary prevention of coronary heart disease (CHD) and stroke. Recent well-controlled clinical studies also suggest the long-term usage of statins is sale in terms of all causes of mortality, including cancers. The incidence of myopathy, which is a concern of most physicians, is relatively low from new clinical evidence. The effectiveness of statins for prevention of CHD also is shown in diabetics. The mechanisms of prevention of CHD by statins are multifactorial, including reversal of endothelial dysfunction. The cost-effectiveness of using statins in the treatment of CHD and stroke is obvious, which should encourage primary care physicians to treat those patients who need lipid-lowering therapy.
Original language | English |
---|---|
Pages (from-to) | 1-11 |
Number of pages | 11 |
Journal | Acta Cardiologica Sinica |
Volume | 19 |
Issue number | 1 |
Publication status | Published - Mar 2003 |
Fingerprint
Keywords
- Coronary heart disease
- Effectiveness
- Safety
- Statin
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Statins in lipid-lowering therapy. / Zhao, Hai Lu; Thomas, G. Neil; Leung, Wilson Y S; Tomlinson, Brian; Hsieh, Ming Hsiung; Chan, Paul.
In: Acta Cardiologica Sinica, Vol. 19, No. 1, 03.2003, p. 1-11.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Statins in lipid-lowering therapy
AU - Zhao, Hai Lu
AU - Thomas, G. Neil
AU - Leung, Wilson Y S
AU - Tomlinson, Brian
AU - Hsieh, Ming Hsiung
AU - Chan, Paul
PY - 2003/3
Y1 - 2003/3
N2 - The discovery of the inhibitors of 3-hydroxy-3-methylglutaryl- coenzyme A (HMG-CoA) reductase (so called statins) is a great step forward in clinical pharmacology and therapeutics. Substantial clinical evidence suggests that statins are effective in the primary and secondary prevention of coronary heart disease (CHD) and stroke. Recent well-controlled clinical studies also suggest the long-term usage of statins is sale in terms of all causes of mortality, including cancers. The incidence of myopathy, which is a concern of most physicians, is relatively low from new clinical evidence. The effectiveness of statins for prevention of CHD also is shown in diabetics. The mechanisms of prevention of CHD by statins are multifactorial, including reversal of endothelial dysfunction. The cost-effectiveness of using statins in the treatment of CHD and stroke is obvious, which should encourage primary care physicians to treat those patients who need lipid-lowering therapy.
AB - The discovery of the inhibitors of 3-hydroxy-3-methylglutaryl- coenzyme A (HMG-CoA) reductase (so called statins) is a great step forward in clinical pharmacology and therapeutics. Substantial clinical evidence suggests that statins are effective in the primary and secondary prevention of coronary heart disease (CHD) and stroke. Recent well-controlled clinical studies also suggest the long-term usage of statins is sale in terms of all causes of mortality, including cancers. The incidence of myopathy, which is a concern of most physicians, is relatively low from new clinical evidence. The effectiveness of statins for prevention of CHD also is shown in diabetics. The mechanisms of prevention of CHD by statins are multifactorial, including reversal of endothelial dysfunction. The cost-effectiveness of using statins in the treatment of CHD and stroke is obvious, which should encourage primary care physicians to treat those patients who need lipid-lowering therapy.
KW - Coronary heart disease
KW - Effectiveness
KW - Safety
KW - Statin
UR - http://www.scopus.com/inward/record.url?scp=0038612802&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038612802&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0038612802
VL - 19
SP - 1
EP - 11
JO - Acta Cardiologica Sinica
JF - Acta Cardiologica Sinica
SN - 1011-6842
IS - 1
ER -